Drug firm Alembic Pharmaceuticals has received tentative approval from the US health regulator for Ticagrelor tablets, used to reduce the rate of cardiovascular death and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
"The company has got tentative approval from the US Food and Drug Administration (USFDA) to market the drug in the strength of 90 mg," Alembic Pharmaceuticals said in a BSE filing.
The tentatively approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug product (RLD), Brilinta tablets of Astrazeneca Pharmaceuticals LP.
Quoting IQVIA sales data, the company said, Ticagrelor tablets, 90 mg had an estimated market size of USD 625 million for 12 months, ending December 2017.
The company said it now has a total of 75 ANDA approvals from the USFDA.
The company's stock was trading at Rs 540, up 1.71 per cent, on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app